Z Cao, W Gao, H Bao, H Feng, S Mei… - … England Journal of …, 2023 - Mass Medical Soc
Background Nirmatrelvir–ritonavir has been authorized for emergency use by many countries for the treatment of coronavirus disease 2019 (Covid-19). However, the supply …
DS Moirangthem, L Surbala - Current Drug Targets, 2021 - ingentaconnect.com
Background: Since its initial start in December 2019 at Wuhan, China, the coronavirus disease 2019 (COVID-19) has been rapidly spreading and labelled as a pandemic by the …
W Liu, M Zhang, C Hu, H Song, Y Mei, Y Liu, Q Zhang - Viruses, 2023 - mdpi.com
Coronaviruses represent a significant threat to both human and animal health, encompassing a range of pathogenic strains responsible for illnesses, from the common …
Despite the wide availability of several safe and effective vaccines that can prevent severe COVID-19 disease, the emergence of SARS-CoV-2 variants of concern (VOC) that can …
N Xiao, X Huang, X Kang, W Zang, B Li, S Kiselev - Medicine, 2023 - journals.lww.com
Background: Recent trials have highlighted the potential of oral antiviral VV116 in the treatment of patients with mild COVID-19. However, no comprehensive studies have …
Y Zhang, Y Sun, Y Xie, W Shang, Z Wang… - Signal transduction and …, 2023 - nature.com
During the ongoing pandemic, providing treatment consisting of effective, low-cost oral antiviral drugs at an early stage of SARS-CoV-2 infection has been a priority for controlling …
Y Wang, F Zhou, D Zhang, J Zhao, R Du, Y Hu… - 2020 - europepmc.org
Background: A novel coronavirus emerged in Wuhan, Hubei Province, China towards the end of 2019 (SARS-CoV-2 or COVID-19 virus). Large scale spread within China and …
X Fan, X Dai, Y Ling, L Wu, L Tang, C Peng… - The Lancet Infectious …, 2024 - thelancet.com
Summary Background Spread of SARS-CoV-2 led to a global pandemic, and there remains unmet medical needs in the treatment of Omicron infections. VV116, an oral antiviral agent …
Recent international epidemics of coronavirus-associated illnesses underscore the urgent medical and public health need for vaccine development and regulatory body approved …